Gain Therapeutics (GANX) Competitors $1.56 -0.01 (-0.64%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GANX vs. HURA, DRUG, CRBP, ACTU, SGMT, STRO, CRBU, TSVT, CKPT, and NKTXShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include TuHURA Biosciences (HURA), Bright Minds Biosciences (DRUG), Corbus Pharmaceuticals (CRBP), Actuate Therapeutics (ACTU), Sagimet Biosciences (SGMT), Sutro Biopharma (STRO), Caribou Biosciences (CRBU), 2seventy bio (TSVT), Checkpoint Therapeutics (CKPT), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. TuHURA Biosciences Bright Minds Biosciences Corbus Pharmaceuticals Actuate Therapeutics Sagimet Biosciences Sutro Biopharma Caribou Biosciences 2seventy bio Checkpoint Therapeutics Nkarta TuHURA Biosciences (NASDAQ:HURA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk. Do insiders and institutionals have more ownership in HURA or GANX? 0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 11.7% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable earnings and valuation, HURA or GANX? TuHURA Biosciences has higher earnings, but lower revenue than Gain Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$8.32MN/AN/AGain Therapeutics$50K827.58-$22.27M-$1.10-1.42 Do analysts prefer HURA or GANX? TuHURA Biosciences currently has a consensus target price of $13.00, indicating a potential upside of 190.18%. Gain Therapeutics has a consensus target price of $7.25, indicating a potential upside of 364.74%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than TuHURA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more volatility and risk, HURA or GANX? TuHURA Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Does the media refer more to HURA or GANX? In the previous week, TuHURA Biosciences had 7 more articles in the media than Gain Therapeutics. MarketBeat recorded 7 mentions for TuHURA Biosciences and 0 mentions for Gain Therapeutics. TuHURA Biosciences' average media sentiment score of 0.82 beat Gain Therapeutics' score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Overall Sentiment TuHURA Biosciences Positive Gain Therapeutics Neutral Does the MarketBeat Community prefer HURA or GANX? Gain Therapeutics received 32 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 70.83% of users gave Gain Therapeutics an outperform vote. CompanyUnderperformOutperformTuHURA BiosciencesOutperform Votes2100.00% Underperform VotesNo VotesGain TherapeuticsOutperform Votes3470.83% Underperform Votes1429.17% Is HURA or GANX more profitable? TuHURA Biosciences' return on equity of 0.00% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A N/A -152.88% Gain Therapeutics N/A -203.91%-128.05% SummaryTuHURA Biosciences and Gain Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.38M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.4210.5991.3417.19Price / Sales827.58195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book1.615.104.794.78Net Income-$22.27M$151.51M$120.07M$225.60M7 Day Performance-4.29%-2.15%-1.90%-1.23%1 Month Performance-4.29%-3.14%11.45%3.37%1 Year Performance-37.60%11.50%30.63%16.58% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics2.4871 of 5 stars$1.56-0.6%$7.25+364.7%-36.1%$41.38M$50,000.00-1.4220HURATuHURA BiosciencesN/A$4.14-16.0%$15.00+262.3%N/A$175.06MN/A0.00N/AAnalyst ForecastNews CoverageDRUGBright Minds Biosciences3.5821 of 5 stars$39.31-4.1%$75.00+90.8%+2,621.8%$174.30MN/A-60.29N/ANews CoverageCRBPCorbus Pharmaceuticals3.8067 of 5 stars$14.31-5.1%$62.00+333.3%+147.6%$174.30M$880,000.00-3.2240ACTUActuate TherapeuticsN/A$8.81+2.2%N/AN/A$172.08MN/A0.0010Gap UpSGMTSagimet Biosciences2.3237 of 5 stars$5.61+27.8%$23.00+310.0%-8.0%$172.06M$2M0.008Gap UpHigh Trading VolumeSTROSutro Biopharma4.4638 of 5 stars$2.07-2.4%$11.13+437.4%-51.3%$170.69M$153.73M-1.32240CRBUCaribou Biosciences2.2043 of 5 stars$1.88-1.6%$10.20+442.6%-69.4%$170.24M$11.48M-1.16100Positive NewsTSVT2seventy bio2.2124 of 5 stars$3.26-0.3%$9.00+176.1%-7.1%$168.18M$100.39M-1.76440Positive NewsCKPTCheckpoint Therapeutics3.8163 of 5 stars$3.41-7.1%$10.33+203.0%+113.1%$166.51M$100,000.00-1.8310Insider TradeNews CoverageGap UpHigh Trading VolumeNKTXNkarta2.7945 of 5 stars$2.31-1.3%$15.00+549.4%-35.4%$163.01MN/A-1.24140Gap Up Related Companies and Tools Related Companies TuHURA Biosciences Alternatives Bright Minds Biosciences Alternatives Corbus Pharmaceuticals Alternatives Actuate Therapeutics Alternatives Sagimet Biosciences Alternatives Sutro Biopharma Alternatives Caribou Biosciences Alternatives 2seventy bio Alternatives Checkpoint Therapeutics Alternatives Nkarta Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GANX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GANX Stock Alerts